Naveen Pereira, MD
Advanced Heart Failure and Transplant Cardiology · Rochester, MNNPI 1386752244
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,865 of the $3,357 with a category attached, or 85.4%. E.r. Squibb & Sons, L.L.C. accounts for 85.4% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $2,865, more than ten times the $235 reported in 2022.
Across 4 payments — averaging $839.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Penumbra, Inc.$235
- Abbott$133
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$124
Across 11 payments — averaging $20,719 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$125K
- AstraZeneca$56K
- Pfizer$46K
What the payments were for
- Consulting fees$2,86585%
- Food & beverage$49215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $2,865 |
| Penumbra, Inc. | 1 | $235 |
| Abbott | 1 | $133 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $124 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,357 in reported general payments places this provider in the 70th percentile of 32 advanced heart failure and transplant cardiology providers in Minnesota.
See all advanced heart failure and transplant cardiology providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 43 | $45,140 |
| EntrestoSacubitril/Valsartan | 29 | $39,292 |
| FarxigaDapagliflozin Propanediol | 34 | $37,516 |
| Sirolimus | 16 | $19,268 |
| Mycophenolate Mofetil | 13 | $1,261 |
| Metoprolol Succinate | 44 | $1,106 |
| Clonidine | 11 | $793 |
| Rosuvastatin Calcium | 18 | $382 |
| Losartan Potassium | 40 | $381 |
| Carvedilol | 19 | $286 |
| Furosemide | 31 | $256 |
| Spironolactone | 29 | $236 |
| Potassium Chloride | 13 | $154 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $79 |
| Pantoprazole Sodium | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Rochester
- Barry BorlaugRochester$173K
- Robert FrantzRochester$141K
- Omar AbouezzeddineRochester$10K
- Swaiman SinghRochester$9K
- Dipan UppalRochester$4K
- Farris TimimiRochester$3K
- Rosalyn AdigunRochester$2K
- Atta BehfarRochester$2K
- Arindam SharmaRochester$2K
- Alfredo ClavellRochester$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.